OpenCitations
metadata only
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity In Patients With Relapsed/Refractory B-Cell Malignancies
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL#880492
- Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia#848134
- The Btk Inhibitor Ibrutinib (PCI-32765) In Combination With Rituximab Is Well Tolerated And Displays Profound Activity In High-Risk Chronic Lymphocytic Leukemia (CLL) Patients#19599
- Ibrutinib treatment inhibits breast cancer progression and metastasis by inducing conversion of myeloid-derived suppressor cells to dendritic cells#1135522
- CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies#148759
Record · ID 19632
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive